Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

AI in Drug Discovery Has Great Potential – But Also Significant Barriers

Posted on May 1st, 2019 by

Pharma R&D

Elsevier’s Tim Miller’s article in World Pharma Today provides a insightful lens into the reality behind the complexities of implementing artificial intelligence into the R&D cycle. While great strides have been made, the runway to realize the potential is a long one and there are many exciting discoveries left to be made and obstacles to overcome.

(more…)

Medicare May Join Forces with Apple Watch to Monitor Consumer Health

Posted on May 1st, 2019 by

Pharma R&D

Istanbul, Turkey – September 6, 2015: A woman wearing 42mm stainless steel Apple Watch with white sports band. The Apple Watch became available April 24, 2015, bringing a new way to receive information at a glance, using apps designed specifically for the wrist.

Apple is a company that has long been thought of us an innovator that has brought consumers an array of enticing gadgets, from home computers to iPods to smartphones. This technology has been transformative for its users, but mostly it has been associated with work and play. Increasingly, though, Apple appears to be interested in getting involved in another critical part of our lives: our health.

(more…)

Three factors to unlock the value of AI for life sciences

Posted on May 1st, 2019 by

Pharma R&D

Artificial Intelligence (AI) has been at the top of many boardroom agendas for the last several years, as execs try to integrate the technology. Recent RELX research found that, across all industries, 88 percent of senior executives believe AI will help their businesses be more competitive. In the life sciences, AI has the potential to scale the benefits of precision medicine or automated disease prediction to more patients across the world, and could generate more than $150 billion in savings for the healthcare industry by 2025. 

3d rendering robot hand working with security laptop
(more…)

Elsevier is recognized as ‘Best of Show Award Finalist’ and ‘Innovative Practices Finalist” at Bio-IT World Conference & Expo 2019

Posted on April 29th, 2019 by

Pharma R&D

Elsevier held a prominent place at last weeks Bio-IT World conference, recognized as a finalist for both ‘Best of Show’ as well as ‘People’s Choice. Highlighted was Elsevier’s Entellect, a new platform for integrated data management in pharmaceutical and life sciences industries.

(more…)

The Cancer-Killing Nanorobots are Coming

Posted on April 26th, 2019 by

Pharma R&D

In recent years, robotics, AI, and Machine Intelligence have been at the forefront of the symbiotic need for humans and our own AI technology to work together. Last year, ground breaking research by molecular chemists at Arizona State University has taken cancer research and treatment to a new level. They are in the process of developing an “origami-inspired” system that can identify the tumor, attack, and deploy a mechanism to suffocate the tumor. Innovation is everywhere in this field, and this one is truly amazing.

(more…)

On World Malaria Day, Assessing Progress in the Fight Against a Persistent Disease

Posted on April 25th, 2019 by

Pharma R&D

Today marks the WHO’s worldwide recognition of those affected by malaria and the widespread global effort to develop a cure. The Elsevier Professional Services team exemplifies this effort with the creation of a database covering interactions and functions of P. faciparum proteins. This is the deadliest of the Plasmodium species that cause malaria in human beings.

(more…)

  1. 1
  2. 2
  3. 3
  4. …
  5. 65


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.